Insulin glargine: long-acting basal insulin analog for improved metabolic control

被引:25
作者
Gerich, JE [1 ]
机构
[1] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA
关键词
basal insulin; insulin glargine; pharmacokinetics;
D O I
10.1185/030079903125002711
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The primary aim of insulin therapy is to replace endogenous insulin secretion in patients with type 1 or type 2 diabetes in a physiologically sound manner, mimicking normal secretion patterns to adequately regulate glucose metabolism. The currently available human insulins for basal therapy - neutral protamine Hagedorn (NPH), Lente* and Ultralentedagger - and analogs such as insulin glargine, differ in pharmacokinetic properties. Clinical trial data indicate that insulin glargine may satisfy basal insulin requirements, with an improved safety profile relative to other available insulins used for basal supplementation. This review describes the unique pharmacokinetic properties and clinical efficacy of insulin glargine.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 26 条
[1]   Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus [J].
Anderson, JH ;
Brunelle, RL ;
Keohane, P ;
Koivisto, VA ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (11) :1249-1255
[2]   Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment [J].
Anderson, JH ;
Brunelle, RL ;
Koivisto, VA ;
Pfutzner, A ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R ;
Bowen, KM ;
Cameron, DP ;
Nankervis, AJ ;
Roberts, AP ;
Zimmet, P ;
Borkenstein, MH ;
Schernthaner, G ;
Waldhausl, WK ;
DeLeeuw, IH ;
Fery, F ;
Scheen, A ;
Somers, G ;
Fettes, IM ;
Tildesley, HD ;
Toth, EL ;
Viikari, J ;
Altman, JJ ;
Bougneres, PF ;
Drouin, P ;
Fossati, P ;
Guillausseau, PJ ;
Marechaud, E ;
Riou, JP ;
Selam, JL ;
Vialettes, PB ;
Beyer, J ;
Federlin, K ;
Fussganger, RD ;
Gries, FA ;
Jastram, HU ;
Koop, I ;
Landgraf, R ;
Rosak, C ;
Schatz, H ;
SchulzeSchleppinghoff, B ;
Seif, FJ ;
Stoeckmann, F ;
Karasik, A ;
Weitzman, S ;
Andreani, D ;
Bompiani, G ;
Crepaldi, G ;
Giorgino, R .
DIABETES, 1997, 46 (02) :265-270
[3]   Growth promoting and metabolic activity of the human insulin analogue [Gly(A21),Arg(B31),Arg(B32)]insulin (HOE 901) in muscle cells [J].
Bahr, M ;
Kolter, T ;
Seipke, G ;
Eckel, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 320 (2-3) :259-265
[4]  
BOLLI GB, 1984, DIABETES, V33, P1150, DOI 10.2337/diabetes.33.12.1150
[5]   GLUCOSE COUNTER-REGULATION AND WANING OF INSULIN IN THE SOMOGYI PHENOMENON (POSTHYPOGLYCEMIC HYPERGLYCEMIA) [J].
BOLLI, GB ;
GOTTESMAN, IS ;
CAMPBELL, PJ ;
HAYMOND, MW ;
CRYER, PE ;
GERICH, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (19) :1214-1219
[6]   MONOMERIC INSULINS AND THEIR EXPERIMENTAL AND CLINICAL IMPLICATIONS [J].
BRANGE, J ;
OWENS, DR ;
KANG, S ;
VOLUND, A .
DIABETES CARE, 1990, 13 (09) :923-954
[7]  
Del Sindaco P, 1998, DIABETIC MED, V15, P592
[8]  
GALLOWAY JA, 1990, CLIN THER, V12, P460
[9]   Hypoglycemia and insulin analogues: Is there a reduction in the incidence? [J].
Heinemann, L .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1999, 13 (02) :105-114
[10]   Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo [J].
Heinemann, L ;
Linkeschova, R ;
Rave, K ;
Hompesch, B ;
Sedlak, M ;
Heise, T .
DIABETES CARE, 2000, 23 (05) :644-649